NCT07231939 Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
| NCT ID | NCT07231939 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2025-11-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
Eligibility Criteria
Inclusion Criteria: * all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available Exclusion Criteria: * unavailability of variables required for the analysis, volume * contrast agent volume \<50 mL or \>500 mL.
Contact & Investigator
Jacek Kubica, Prof.
PRINCIPAL INVESTIGATOR
Collegium Medicum w Bydgoszczy
Frequently Asked Questions
Who can join the NCT07231939 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07231939 currently recruiting?
Yes, NCT07231939 is actively recruiting participants. Contact the research team at piotr.niezgoda1986@gmail.com for enrollment information.
Where is the NCT07231939 trial being conducted?
This trial is being conducted at Bydgoszcz, Poland.
Who is sponsoring the NCT07231939 clinical trial?
NCT07231939 is sponsored by Collegium Medicum w Bydgoszczy. The principal investigator is Jacek Kubica, Prof. at Collegium Medicum w Bydgoszczy. The trial plans to enroll 4,000 participants.